Cleveland Medical Devices Inc. (CleveMed) was just issued a new patent (US Patent No. 10,076,269) entitled “Devices and methods for sleep disorder diagnosis and treatment”. The patent covers technologies that enable data transfer from home sleep apnea therapy (CPAP) to the cloud through software apps on patients’ cell phones or other personal smart devices such as wearables. “There is a tremendous need to allow healthcare providers and patients easy access to therapy efficacy data, especially long-term. Not only will this permit healthcare providers a deeper understanding of patient’s response to therapy through larger data aggregation, easy patient access of their own data improves their engagement with therapy. As numerous research articles have shown, stronger patient engagement leads to better treatment compliance”, stated Hani Kayyali, CleveMed CEO.
“This new patent is another one in a long line of patents that establish CleveMed’s technology leadership in data acquisition from the home for patients suffering from chronic sleep disorders,” stated Brian Kolkowski, CleveMed’s Executive Vice President and General Counsel, “We expect our Intellectual Property in this area to continue to grow given a number of pending applications currently being prosecuted.”
Obstructive sleep apnea (OSA), the most prevalent form of sleep apnea, is a repeated interruption of normal breathing during sleep due to a collapse of the upper airway. It is estimated to impact as many people as asthma and diabetes; yet, up to 80 percent of the population with the disease remain undiagnosed and untreated. Moreover, OSA leads to serious health and economic consequences. Numerous studies link OSA to major chronic diseases such as stroke, heart failure, diabetes, obesity, hypertension and increased odds of serious car crash injuries.